| Literature DB >> 35250890 |
Xing Yu1, Yuancong Jiang2, Yujun Li2, Qionghua He2, Lei Pan2, Peifeng Zhu2, Yong Wang1, Ping Wang1.
Abstract
BACKGROUND: The influences of patients' different mandibular jawlines on transoral endoscopic thyroidectomy via vestibular approach (TOETVA) have not been described before. The objective of this study was to introduce a new classification to assess different mandibular jawlines, and to evaluate the effects on TOETVA in terms of safety, feasibility, and postoperative feelings in the treatment of papillary thyroid carcinoma (PTC).Entities:
Keywords: length of jay; mandibular jawlines; papillary thyroid carcinoma; surgical outcomes; transoral endoscopic thyroidectomy
Mesh:
Year: 2022 PMID: 35250890 PMCID: PMC8891504 DOI: 10.3389/fendo.2022.842148
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Schematic diagram and realistic photos of the three classifications: (A) (angle: 80° ~ 110°), (B) (angle > 110°), and (C) (angle < 80°) types.
Figure 2The length of jay was measured from anterior neck plane to the anterior border plane of jaw (red line) in the three groups.
Comparation of clinicopathological characteristics in the groups of type A, B, and C.
| Type A (n = 342) | Type B (n = 281) | Type C (n = 67) |
| |
|---|---|---|---|---|
| Age (years) | 37.3 ± 9.8 | 37.6 ± 9.9 | 35.8 ± 9.2 | 0.423 |
| Male (%) | 90 (26.3%) | 74 (26.3%) | 25 (37.3%) | 0.159 |
| BMI (kg/m2) | 23.7 ± 3.7 | 23.7 ± 3.7 | 23.9 ± 3.8 | 0.825 |
| Max tumor size (cm) | 1.23 ± 0.59 | 1.20 ± 0.61 | 1.31 ± 0.71 | 0.175 |
| Multiple lesions (%) | 81 (23.7%) | 88 (31.3%) | 22 (32.8%) | 0.065 |
| Hashimoto’s thyroiditis (%) | 100 (29.2%) | 97 (34.5%) | 25 (27.3%) | 0.238 |
| Total thyroidectomy (%) | 111 (32.5%) | 98 (34.9%) | 25 (37.3%) | 0.675 |
| Bilateral CND (%) | 108 (31.6%) | 96 (34.2%) | 19 (28.4%) | 0.606 |
| Length of jaw (cm) | 6.85 ± 0.23 | 6.17 ± 0.42 | 7.26 ± 0.23 | <0.01 |
BMI, body mass index; CND, central node dissection.
Effective assessment of surgical results in the groups of type A, B, and C malocclusion.
| Type A | Type B | Type C |
| |
|---|---|---|---|---|
| (n = 342) | (n = 281) | (n = 67) | ||
| EMG changes (%) | 28 (8.2%) | 21 (7.5%) | 2 (3.0%) | 0.330 |
| Transient vocal cord paralysis (%) | 7 (2.0%) | 9 (3.2%) | 1 (1.5%) | 0.563 |
| Postoperative PTH (pg/ml) | 34.7 ± 16.5 | 36.0 ± 18.4 | 35.7 ± 18.9 | 0.642 |
| Postoperative calcium | 2.09 ± 0.14 | 2.11 ± 0.13 | 2.08 ± 0.13 | 0.360 |
| numbness in limbs (%) | 36 (10.5%) | 30 (10.7%) | 10 (14.9%) | 0.559 |
| Total number of CLN | 8.83 ± 5.75 | 9.16 ± 6.14 | 8.67 ± 4.61 | 0.715 |
| Number of metastatic CLN | 1.70 ± 2.41 | 1.64 ± 2.37 | 1.84 ± 2.57 | 0.827 |
| WBC (×109/L) | 9.2 ± 2.7 | 9.5 ± 4.7 | 9.9 ± 2.9 | 0.330 |
| Postoperative CRP (mg/L) | 8.3 ± 7.0 | 9.3 ± 8.3 | 9.4 ± 7.7 | 0.172 |
| Operative time (min) | 116.2 ± 44.3 | 118.5 ± 46.6 | 121.7 ± 40.3 | 0.601 |
| Mandibular swell | 4 (1.2%) | 2 (0.7%) | 7 (10.4%) | <0.01 |
| Visual VAS | 1.7 ± 0.5 | 1.7 ± 0.5 | 2.1 ± 0.6 | <0.01 |
| Hospital stay (days) | 3.89 ± 1.09 | 3.99 ± 1.07 | 3.88 ± 1.12 | 0.515 |
| Quality of life | 7.89 ± 0.80 | 7.94 ± 0.71 | 7.88 ± 0.69 | 0.609 |
EMG, electromyography; PTH, parathyroid hormone; CLN, central lymph nodes; WBC, white blood cell; CRP, C-reactive protein; VAS, visual analogue scale.
Figure 3Introduce another vacuum tube for working space building in TOETVA.
Figure 4Cosmetic results 1 month and 6 months postoperatively of TOETVA.